Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis

Journal of Experimental Medicine

Volumn 194, Issue 12, 2001, Pages 1789-1799

  Jahng, Alex W ^a   Maricic, Igor ^a   Pedersen, Brian ^a   Burdin, Nicolas ^a   Naidenko, Olga ^a   Kronenberg, Mitchell ^a   Koezuka, Yasuhiko ^b   Kumar, Vipin ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b KIRIN BREWERY CO LTD   (Japan)

Author keywords

galactosylceramide; CD1d; Experimental autoimmune encephalomyelitis; Immunotherapy; NKT cells

Indexed keywords

CD1 ANTIGEN; GALACTOSYLCERAMIDE; GAMMA INTERFERON; INTERLEUKIN 4; MYELIN; MYELIN BASIC PROTEIN; T LYMPHOCYTE RECEPTOR;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; FEMALE; IMMUNE RESPONSE; MOUSE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TH1 CELL;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD1; CYTOTOXICITY, IMMUNOLOGIC; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GALACTOSYLCERAMIDES; IMMUNOTHERAPY; KILLER CELLS, NATURAL; MICE; MICE, INBRED C57BL; MYELIN SHEATH;

EID: 0035905485     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.194.12.1789     Document Type: Article

References (52)

1. Mouse CD1-specific NK1 T cells: Development, specificity, and function
2. The CD1 system: Antigen-presenting molecules for T cell recognition of lipids and glycolipids
3. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides
4. CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells
5. CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution
6. CD4(+) v(alpha)14 NKT cells play a crucial role in an early stage of protective immunity against infection with Leishmania major
7. Differential tumor surveillance by natural killer (NK) and NKT cells
8. Immune suppression and skin cancer development: Regulation by NKT cells
9. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway
10. CD1-reactive natural killer T cells are required for development of systemic tolerance through an immune-privileged site
11. Immune privilege: Keeping an eye on natural killer T cells
12. Selective reduction of T cells bearing invariant V alpha 24J alpha Q antigen receptor in patients with systemic sclerosis
13. Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes
14. Differential expression of NK T cell V alpha 24J alpha Q invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy
15. + double-negative regulatory natural killer T cells in autoimmune diseases
16. Decreases in interleukin-4 secretion by invariant CD4(-)CD8(-)V alpha 24J alpha Q T cells in peripheral blood of patients with relapsing- remitting multiple sclerosis
17. +-like thymocytes in the NOD mouse
18. - T-cell deficiency and IDDM in NOD/Lt mice
19. A defect in interleukin 12-induced activation and interferon gamma secretion of peripheral natural killer T cells in nonobese diabetic mice suggests new pathogenic mechanisms for insulin-dependent diabetes mellitus
20. + NK T cells associated with disease development in autoimmune-prone mice
21. CD1d-restricted NKT cells: An interstrain comparison
22. + T cells that promptly produce interleukin 4
23. + NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage
24. CD1, tuberculosis, and the evolution of major histocompatibility complex molecules
25. Murine CD1d-restricted T cell recognition of cellular lipids
26. Immunization with alpha-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis
27. Cutting edge: Activation of NK T cells by CD1d and alpha-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype
28. Autoimmune diseases of myelin
29. The T-cell receptor repertoire and autoimmune diseases
30. Restricted use of T cell receptor V genes in murine autoimmune encephalomyelitis raises possibilities for antibody therapy
31. + T cells in recovery from antigen-induced autoimmune disease
32. Inactivation of T cell receptor peptide-specific CD4 regulatory T cells induces chronic experimental autoimmune encephalomyelitis (EAE)
33. Induction or protection from experimental autoimmune encephalomyelitis depends on the cytokine secretion profile of TCR peptide-specific regulatory CD4 T cells
34. TCR peptide-reactive T cells and peripheral tolerance to myelin basic protein
35. The T lymphocyte in experimental allergic encephalomyelitis
36. + T-cell subsets in autoimmunity
37. Oral tolerance: Immune mechanisms and the generation of Th3-type TGF- beta-secreting regulatory cells
38. T cell determinant structure of myelin basic protein in B10.PL, SJL/J, and their F1S
39. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers
40. Major histocompatibility complex binding affinity of an antigenic determinant is crucial for the differential secretion of interleukin 4/5 or interferon gamma by T cells
41. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune type 1 diabetes
42. CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes
43. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice
44. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis
45. + T cells
46. Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells
47. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells
48. + T cells upon NK T or T cell activation
49. alpha-galactosylceramide induces early B-cell activation through IL-4 production by NKT cells
50. Cutting edge: CD1d deficiency impairs murine host defense against the spirochete, Borrelia burgdorferi
51. CD1d-reactive T-cell activation leads to amelioration of disease caused by diabetogenic encephalomyocarditis virus
52. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells